CNS Pharmaceuticals, Inc. (CNSP) stock
CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.15+0.67 (+19.25%)
Close on Nov 17, 2026Market cap $6.07MP/E –Yield –
CNS Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
CNS Pharmaceuticals's total assets was $21.94M at Jun 30, 2026. For fiscal 2025 it was $8.62M, down 0.9% from the year before. The highest annual figure on record is $15.85M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.62M | -0.9% |
| FY2024 | Dec 31, 2024 | $8.70M | +411.6% |
| FY2023 | Dec 31, 2023 | $1.70M | -87.0% |
| FY2022 | Dec 31, 2022 | $13.05M | +49.1% |
| FY2021 | Dec 31, 2021 | $8.76M | -44.8% |
| FY2020 | Dec 31, 2020 | $15.85M | +100.4% |
| FY2019 | Dec 31, 2019 | $7.91M | +1057.9% |
| FY2018 | Dec 31, 2018 | $683.33K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $21.94M | +51.2% |
| Q1 FY2026 | Mar 31, 2026 | $4.65M | -66.2% |
| Q4 FY2025 | Dec 31, 2025 | $8.62M | -0.9% |
| Q3 FY2025 | Sep 30, 2025 | $11.87M | +60.2% |
| Q2 FY2025 | Jun 30, 2025 | $14.51M | +487.5% |
| Q1 FY2025 | Mar 31, 2025 | $13.75M | +727.8% |
| Q4 FY2024 | Dec 31, 2024 | $8.70M | +411.6% |
| Q3 FY2024 | Sep 30, 2024 | $7.41M | +218.3% |
| Q2 FY2024 | Jun 30, 2024 | $2.47M | -61.7% |
| Q1 FY2024 | Mar 31, 2024 | $1.66M | -77.6% |
| Q4 FY2023 | Dec 31, 2023 | $1.70M | -87.0% |
| Q3 FY2023 | Sep 30, 2023 | $2.33M | -75.8% |
| Q2 FY2023 | Jun 30, 2023 | $6.45M | -48.2% |
| Q1 FY2023 | Mar 31, 2023 | $7.41M | -53.3% |
| Q4 FY2022 | Dec 31, 2022 | $13.05M | +49.1% |
| Q3 FY2022 | Sep 30, 2022 | $9.64M | -16.2% |
| Q2 FY2022 | Jun 30, 2022 | $12.45M | -12.6% |
| Q1 FY2022 | Mar 31, 2022 | $15.87M | +20.7% |
| Q4 FY2021 | Dec 31, 2021 | $8.76M | -44.8% |
| Q3 FY2021 | Sep 30, 2021 | $11.51M | +285.5% |
| Q2 FY2021 | Jun 30, 2021 | $14.24M | +257.2% |
| Q1 FY2021 | Mar 31, 2021 | $13.14M | +111.6% |
| Q4 FY2020 | Dec 31, 2020 | $15.85M | +100.4% |
| Q3 FY2020 | Sep 30, 2020 | $2.99M | +113.6% |
| Q2 FY2020 | Jun 30, 2020 | $3.99M | +483.3% |
| Q1 FY2020 | Mar 31, 2020 | $6.21M | – |
| Q4 FY2019 | Dec 31, 2019 | $7.91M | – |
| Q3 FY2019 | Sep 30, 2019 | $1.40M | – |
| Q4 FY2018 | Dec 31, 2018 | $683.33K | – |
See a number that looks wrong?